$NERV
Minerva Neurosciences Inc

2019 Q1 Form 10-Q Financial Statement

#000156459019015804 Filed on May 06, 2019

View on sec.gov

Income Statement

Concept 2019 Q1 2018 Q1
Revenue $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.710M $4.290M
YoY Change 9.79% 49.48%
% of Gross Profit
Research & Development $11.61M $8.450M
YoY Change 37.4% 11.04%
% of Gross Profit
Depreciation & Amortization $4.367K $0.00
YoY Change -100.0%
% of Gross Profit
Operating Expenses $16.31M $12.74M
YoY Change 28.04% 21.45%
Operating Profit -$16.31M -$12.74M
YoY Change 28.0% 21.55%
Interest Expense $480.0K -$70.65K
YoY Change -779.42% -64.94%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income -$15.83M -$12.42M
YoY Change 27.46% 16.73%
Income Tax
% Of Pretax Income
Net Earnings -$15.83M -$12.42M
YoY Change 27.45% 16.66%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$406.2K -$320.5K
COMMON SHARES
Basic Shares Outstanding
Diluted Shares Outstanding

Balance Sheet

Concept 2019 Q1 2018 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments $79.20M $121.0M
YoY Change -34.55% 41.69%
Cash & Equivalents $30.61M $45.23M
Short-Term Investments $48.60M $75.90M
Other Short-Term Assets $1.200M $4.300M
YoY Change -72.09% 377.78%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $80.30M $125.3M
YoY Change -35.91% 45.36%
LONG-TERM ASSETS
Property, Plant & Equipment $400.0K $0.00
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $0.00
YoY Change
Other Assets $14.81K $0.00
YoY Change
Total Long-Term Assets $49.50M $49.20M
YoY Change 0.61% 0.2%
TOTAL ASSETS
Total Short-Term Assets $80.30M $125.3M
Total Long-Term Assets $49.50M $49.20M
Total Assets $129.8M $174.5M
YoY Change -25.62% 28.97%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $3.000M $2.800M
YoY Change 7.14% -15.15%
Accrued Expenses $3.900M $2.400M
YoY Change 62.5% -50.0%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due $2.700M
YoY Change -46.0%
Total Short-Term Liabilities $6.900M $7.900M
YoY Change -12.66% -39.23%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change -100.0%
Other Long-Term Liabilities $41.40M $41.20M
YoY Change 0.49%
Total Long-Term Liabilities $41.40M $41.20M
YoY Change 0.49% 1484.62%
TOTAL LIABILITIES
Total Short-Term Liabilities $6.900M $7.900M
Total Long-Term Liabilities $41.40M $41.20M
Total Liabilities $52.40M $53.20M
YoY Change -1.5% 83.45%
SHAREHOLDERS EQUITY
Retained Earnings
YoY Change
Common Stock
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $77.42M $121.3M
YoY Change
Total Liabilities & Shareholders Equity $129.8M $174.5M
YoY Change -25.62% 28.97%

Cashflow Statement

Concept 2019 Q1 2018 Q1
OPERATING ACTIVITIES
Net Income -$15.83M -$12.42M
YoY Change 27.45% 16.66%
Depreciation, Depletion And Amortization $4.367K $0.00
YoY Change -100.0%
Cash From Operating Activities -$9.601M -$10.93M
YoY Change -12.18% 80.99%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities -$10.55M $31.32M
YoY Change -133.68% -290.05%
Cash From Investing Activities -$10.55M $31.32M
YoY Change -133.69% -290.02%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 525.0K -1.290M
YoY Change -140.7% -115.28%
NET CHANGE
Cash From Operating Activities -9.601M -10.93M
Cash From Investing Activities -10.55M 31.32M
Cash From Financing Activities 525.0K -1.290M
Net Change In Cash -19.63M 19.09M
YoY Change -202.79% -235.61%
FREE CASH FLOW
Cash From Operating Activities -$9.601M -$10.93M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2019Q1 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2019Q1 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2019Q1 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2019
CY2019Q1 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q1
CY2019Q1 dei Entity Small Business
EntitySmallBusiness
true
CY2019Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2018Q4 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2019Q1 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
14808
CY2019Q1 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
371370
CY2019Q1 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
156159
CY2019Q1 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4057488
CY2019Q1 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
243115
CY2018Q4 us-gaap Deferred Income Tax Liabilities Net
DeferredIncomeTaxLiabilitiesNet
4057488
CY2019Q1 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41175600
CY2018Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
41175600
CY2018Q4 us-gaap Intangible Assets Net Excluding Goodwill
IntangibleAssetsNetExcludingGoodwill
34200000
CY2018Q4 us-gaap Goodwill
Goodwill
14869399
CY2018Q4 us-gaap Assets
Assets
139136045
CY2018Q1 us-gaap Net Income Loss
NetIncomeLoss
-12418263
CY2018Q1 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
38749343
CY2017Q4 us-gaap Stockholders Equity
StockholdersEquity
131597444
CY2018Q1 us-gaap Stockholders Equity
StockholdersEquity
121293117
CY2019Q1 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
525000
CY2019Q1 us-gaap Profit Loss
ProfitLoss
-15827200
CY2018Q1 us-gaap Profit Loss
ProfitLoss
-12418263
CY2019Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
242708
CY2018Q1 us-gaap Investment Income Net Amortization Of Discount And Premium
InvestmentIncomeNetAmortizationOfDiscountAndPremium
54212
CY2019Q1 us-gaap Amortization Of Leased Asset
AmortizationOfLeasedAsset
34622
CY2019Q1 nerv Increase Decrease In Operating Lease Liabilities Current
IncreaseDecreaseInOperatingLeaseLiabilitiesCurrent
20609
CY2018Q1 us-gaap Increase Decrease In Other Noncurrent Liabilities
IncreaseDecreaseInOtherNoncurrentLiabilities
395
CY2019Q1 nerv Increase Decrease In Operating Lease Liabilities Noncurrent
IncreaseDecreaseInOperatingLeaseLiabilitiesNoncurrent
-41016
CY2019Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-9600592
CY2019Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
490984
CY2018Q1 us-gaap Investment Income Interest
InvestmentIncomeInterest
414307
CY2018Q1 us-gaap Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
-70649
CY2018Q1 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-10931732
CY2019Q1 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
9000000
CY2018Q1 us-gaap Proceeds From Sale And Maturity Of Held To Maturity Securities
ProceedsFromSaleAndMaturityOfHeldToMaturitySecurities
39250000
CY2018Q1 us-gaap Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
7934482
CY2019Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-10551411
CY2018Q1 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
31315518
CY2019Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
525000
CY2018Q1 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
-1289882
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-19627003
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
19093904
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
50334871
CY2017Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
26131821
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
30707868
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
45225725
CY2018Q1 us-gaap Interest Paid Net
InterestPaidNet
53975
CY2018Q1 us-gaap Restricted Cash Current
RestrictedCashCurrent
100000
CY2019Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
30707868
CY2018Q1 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
45225725
CY2019Q1 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:12pt;margin-left:2.27%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of estimates </p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosures of contingent assets and liabilities at the date of the financial statements and the reported amounts of expenses during the reporting period. Actual results could differ from those estimates. </p>
CY2019Q1 us-gaap Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
<p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Concentration of credit risk</p> <p style="margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to concentrations of credit risk are primarily cash, cash equivalents and marketable securities. The Company maintains its cash and cash equivalent balances in the form of business checking accounts and money market accounts, the balances of which, at times, may exceed federally insured limits. Exposure to cash and cash equivalents credit risk is reduced by placing such deposits with major financial institutions and monitoring their credit ratings. Marketable securities consist primarily of corporate bonds, with fixed interest rates. Exposure to credit risk of marketable securities is reduced by maintaining a diverse portfolio and monitoring their credit ratings.</p>
CY2019Q1 nerv Cash Cash Equivalents Restricted Cash And Marketable Securities
CashCashEquivalentsRestrictedCashAndMarketableSecurities
79300000
CY2018Q4 us-gaap Held To Maturity Securities Amortized Cost Before Other Than Temporary Impairment
HeldToMaturitySecuritiesAmortizedCostBeforeOtherThanTemporaryImpairment
37762439
CY2019Q1 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
48568165
CY2018Q4 us-gaap Held To Maturity Securities Fair Value
HeldToMaturitySecuritiesFairValue
37757896
CY2018Q4 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Gain
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingGain
4543
CY2019Q1 us-gaap Held To Maturity Securities Accumulated Unrecognized Holding Loss
HeldToMaturitySecuritiesAccumulatedUnrecognizedHoldingLoss
11607
CY2019Q1 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
48556558
CY2018Q4 us-gaap Held To Maturity Securities
HeldToMaturitySecurities
37762439
CY2019Q1 us-gaap Property Plant And Equipment Useful Life
PropertyPlantAndEquipmentUsefulLife
P3Y
CY2019Q1 us-gaap Revenue From Contract With Customer Excluding Assessed Tax
RevenueFromContractWithCustomerExcludingAssessedTax
0
CY2019Q1 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2019Q1 nerv Accrued Research And Development Costs And Other Expenses Current
AccruedResearchAndDevelopmentCostsAndOtherExpensesCurrent
2572814
CY2019Q1 us-gaap Accrued Bonuses Current
AccruedBonusesCurrent
501014
CY2019Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
395497
CY2018Q1 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
455545
CY2019Q1 us-gaap Accrued Vacation Current
AccruedVacationCurrent
251630
CY2018Q1 us-gaap Accounts Payable And Other Accrued Liabilities Current
AccountsPayableAndOtherAccruedLiabilitiesCurrent
1809532
CY2015Q1 us-gaap Warrants Not Settleable In Cash Fair Value Disclosure
WarrantsNotSettleableInCashFairValueDisclosure
200000
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
5.17
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
200000
CY2018Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue
0
CY2019Q1 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0.00
CY2019Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2461699
CY2018Q1 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
2113936

Files In Submission

Name View Source Status
0001564590-19-015804-index-headers.html Edgar Link pending
0001564590-19-015804-index.html Edgar Link pending
0001564590-19-015804.txt Edgar Link pending
0001564590-19-015804-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gg2f3m1m31y3000001.jpg Edgar Link pending
gg2f3m1m31y3000002.jpg Edgar Link pending
nerv-10q_20190331.htm Edgar Link pending
nerv-20190331.xml Edgar Link completed
nerv-20190331.xsd Edgar Link pending
nerv-20190331_cal.xml Edgar Link unprocessable
nerv-20190331_def.xml Edgar Link unprocessable
nerv-20190331_lab.xml Edgar Link unprocessable
nerv-20190331_pre.xml Edgar Link unprocessable
nerv-ex101_122.htm Edgar Link pending
nerv-ex311_8.htm Edgar Link pending
nerv-ex312_6.htm Edgar Link pending
nerv-ex321_7.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending